NBB:NYE-Nuveen Build America Bond Closed Fund (USD)

FUND | Staffing & Employment Services |

Last Closing

USD 16.63

Change

-0.10 (-0.60)%

Market Cap

N/A

Volume

0.10M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-02 )

Largest Industry Peers for Staffing & Employment Services

Symbol Name Price(Change) Market Cap
KFY Korn Ferry

-0.54 (-0.73%)

USD 3.80B
ZIP Ziprecruiter Inc

+0.16 (+1.71%)

USD 0.92B
TBI TrueBlue Inc

-0.20 (-2.59%)

USD 0.24B
MHH Mastech Holdings Inc

+0.14 (+1.46%)

USD 0.11B
BGSF BG Staffing Inc

+0.07 (+0.86%)

USD 0.09B
JOB GEE Group Inc

N/A

USD 0.03B
MAN ManpowerGroup Inc

-1.22 (-1.68%)

N/A
TNET TriNet Group Inc

-0.36 (-0.37%)

N/A
NSP Insperity Inc

-0.98 (-1.14%)

N/A
RHI Robert Half International Inc

-0.29 (-0.43%)

N/A

ETFs Containing NBB

N/A

Market Performance

  Market Performance vs. Industry/Classification (Staffing & Employment Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.32% 82% B 42% F
Dividend Return 5.38% 100% F 81% B-
Total Return 10.70% 82% B 49% F
Trailing 12 Months  
Capital Gain 15.81% 91% A- 44% F
Dividend Return 10.22% 100% F 92% A
Total Return 26.03% 91% A- 57% F
Trailing 5 Years  
Capital Gain -26.06% 40% F 18% F
Dividend Return 26.35% 100% F 79% B-
Total Return 0.29% 50% F 26% F
Average Annual (5 Year Horizon)  
Capital Gain -6.99% N/A N/A 11% F
Dividend Return -1.18% N/A N/A 18% F
Total Return 5.81% N/A N/A 85% B
Risk Return Profile  
Volatility (Standard Deviation) 13.07% N/A N/A 70% C-
Risk Adjusted Return -9.03% N/A N/A 19% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike